Diabetes Drug Found Ineffective Against COVID-19

In COVID-19, Latest News by Precision Vaccinations

AstraZeneca and Saint Luke’s Mid America Heart Institute announced high-level results of the DARE-19 Phase III trial assessing the potential of Farxiga to treat patients hospitalized with COVID-19 who are at risk of developing serious complications.
The companies confirmed on April 12, 2021, this trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality and the primary endpoint of recovery measuring a change in clinical status (from early recovery to death) at 30 days.

Read More